Upgrade to SI Premium - Free Trial

Corvus Pharmaceuticals (CRVS) Reiterated at Overweight by Cantor Fitzgerald

March 13, 2026 7:23 AM
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Corvus Pharmaceuticals (NASDAQ: CRVS).The analyst commented, "Corvus' 4Q25 earning call ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments